Press Releases :: VolitionRx Ltd (VNRX)

Jul 1, 2014 • 6:30 AM EDT VolitionRx Announces New Chief Financial Officer

Jun 23, 2014 • 6:30 AM EDT VolitionRx Sells First NuQ® Research Use Only Kits to Active Motif

Jun 3, 2014 • 6:30 AM EDT VolitionRx Appoints Dr. Habib Skaff to Board of Directors

Apr 30, 2014 • 6:30 AM EDT VolitionRx Announces First Published Data in Anticancer Research Journal

Apr 24, 2014 • 6:30 AM EDT VolitionRx Extends Agreement With University Hospital Bonn to Include CE Mark Performance Evaluation

Apr 2, 2014 • 6:30 AM EDT President and CEO of VolitionRx Issues Corporate Update

Mar 17, 2014 • 8:30 AM EDT New VolitionRx Study Data Demonstrates NuQ(R) Assays' High Detection Rate of Prostate Cancer and the Ability to Distinguish Between Prostate and Colorectal Cancer

Feb 28, 2014 • 6:00 AM EST VolitionRx Completes $3 Million Private Placement

Jan 22, 2014 • 6:00 AM EST VolitionRx Commences First Large Clinical Trial in Collaboration With Hvidovre Hospital, Denmark

Jan 9, 2014 • 8:30 AM EST VolitionRx Presents at MicroCapClub Invitational